Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP85498.RAthB_Ebp3sIKp08ZnpCMrn5OxA4fuICmVuYyNLB_8fP4130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP85498.RAthB_Ebp3sIKp08ZnpCMrn5OxA4fuICmVuYyNLB_8fP4130_provenance.
• NP515369.RAinhCaxv_00nDPbwh4ZniQFakv7m9Rb3JiwvUYmBX1E8130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP515369.RAinhCaxv_00nDPbwh4ZniQFakv7m9Rb3JiwvUYmBX1E8130_provenance.
• NP544368.RAxpkJk8yYcuahMkMT1CHEdIMmFLlH7YdhgqvkLp3Md8k130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP544368.RAxpkJk8yYcuahMkMT1CHEdIMmFLlH7YdhgqvkLp3Md8k130_provenance.
• NP788320.RAnRt9R3yVj1iZ-hEQFSKaHhkr-La9d2usxS-rvJ1C7T0130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP788320.RAnRt9R3yVj1iZ-hEQFSKaHhkr-La9d2usxS-rvJ1C7T0130_provenance.
• NP85489.RAKwJ65w4JlUiBT2QpCsHm07Ly40rFWx4opuTiuek7n9s130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP85489.RAKwJ65w4JlUiBT2QpCsHm07Ly40rFWx4opuTiuek7n9s130_provenance.
• NP604820.RAT3PMqBY-SZM0AWCUS5SsZSV_568HOSaXqHo9xU7IvhI130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP604820.RAT3PMqBY-SZM0AWCUS5SsZSV_568HOSaXqHo9xU7IvhI130_provenance.
• NP381615.RANz28ax3EHgSB_BWmi0FN8WUZ_HiRBlB_ImWZ_i-26Gg130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP381615.RANz28ax3EHgSB_BWmi0FN8WUZ_HiRBlB_ImWZ_i-26Gg130_provenance.
• NP703948.RA4nZ5WaeJQRp0n0zdEQYdqMMufR1TZ_vrd27_-HxCkPk130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP703948.RA4nZ5WaeJQRp0n0zdEQYdqMMufR1TZ_vrd27_-HxCkPk130_provenance.
• NP524273.RAQh3zMBtNNHQUySI57rU1gfQ0slBEBgR6sI9SWV1BbUw130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP524273.RAQh3zMBtNNHQUySI57rU1gfQ0slBEBgR6sI9SWV1BbUw130_provenance.
• NP524382.RAaZlR9fdnsYQDrBb9626opw9XNtQ7-z2_dHvPxzqZWHg130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP524382.RAaZlR9fdnsYQDrBb9626opw9XNtQ7-z2_dHvPxzqZWHg130_provenance.
• assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP133084.RAtZKzdB3hD-r3XziDC4nmCVB491zg8A8Q1blAQ3CLNhA130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP133084.RAtZKzdB3hD-r3XziDC4nmCVB491zg8A8Q1blAQ3CLNhA130_provenance.
• NP133134.RAo_H7UZFS97Ao_9eFiPa7VUGCHHGbIj2MKXhbVjmN2s4130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP133134.RAo_H7UZFS97Ao_9eFiPa7VUGCHHGbIj2MKXhbVjmN2s4130_provenance.
• NP181873.RADyMFLItEvoRS_BbCDlyrOx0TTcxZPsPYbsoBxCQ1C3o130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP181873.RADyMFLItEvoRS_BbCDlyrOx0TTcxZPsPYbsoBxCQ1C3o130_provenance.
• assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP965757.RAqR5bhGN_YHFdb5DVD7SAtSHVnsOODLOxXqcaMrbp-YA130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP965757.RAqR5bhGN_YHFdb5DVD7SAtSHVnsOODLOxXqcaMrbp-YA130_provenance.
• NP181882.RAo_ElFd2uVqo_JQs1m_LS1nJI2gozIKI8gnWM6na3pXQ130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP181882.RAo_ElFd2uVqo_JQs1m_LS1nJI2gozIKI8gnWM6na3pXQ130_provenance.
• NP826981.RAsmPH7RqMLs3xx-LMwDvUqCDkSbfgZRdRlHEvJuv63Sw130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP826981.RAsmPH7RqMLs3xx-LMwDvUqCDkSbfgZRdRlHEvJuv63Sw130_provenance.
• NP146465.RAxGBOriczfzlQzTngfu7MiW2WDvVwoLZzSBaP42AjWlk130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP146465.RAxGBOriczfzlQzTngfu7MiW2WDvVwoLZzSBaP42AjWlk130_provenance.
• NP133164.RAJFI9YZmhk8Pk8MkW_fliM_EYYPEzn64XiRWLxT5PWW0130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP133164.RAJFI9YZmhk8Pk8MkW_fliM_EYYPEzn64XiRWLxT5PWW0130_provenance.
• NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_provenance.
• NP826979.RA3qK45XB5Bu3KdOMvyyT4ZH1HP06TDup6pmhr0Ny-TdQ130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP826979.RA3qK45XB5Bu3KdOMvyyT4ZH1HP06TDup6pmhr0Ny-TdQ130_provenance.
• NP826980.RA2pLvzADwzV6wnDLO7ewKOTkTEieE4FxshlqgTzf3Nk8130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP826980.RA2pLvzADwzV6wnDLO7ewKOTkTEieE4FxshlqgTzf3Nk8130_provenance.
• NP826983.RA2dHBcmFkNwigB27waZcqRpu9coarinnsh5fZPBCtFoY130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP826983.RA2dHBcmFkNwigB27waZcqRpu9coarinnsh5fZPBCtFoY130_provenance.
• NP181871.RA0_UsWY7hvvnnDVoUI2UDq9C11agFNvpA1iUtoAmD7Gw130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP181871.RA0_UsWY7hvvnnDVoUI2UDq9C11agFNvpA1iUtoAmD7Gw130_provenance.
• NP181878.RA93UFTP6QLb2739RjUiOZYJgIj5mL1G_0ho90JxIN4Z8130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP181878.RA93UFTP6QLb2739RjUiOZYJgIj5mL1G_0ho90JxIN4Z8130_provenance.